LIFE vs. BCAB, OTLK, BLUE, VIGL, CRDL, SGMO, OMGA, ALVR, CRIS, and VXRT
Should you be buying aTyr Pharma stock or one of its competitors? The main competitors of aTyr Pharma include BioAtla (BCAB), Outlook Therapeutics (OTLK), bluebird bio (BLUE), Vigil Neuroscience (VIGL), Cardiol Therapeutics (CRDL), Sangamo Therapeutics (SGMO), Omega Therapeutics (OMGA), AlloVir (ALVR), Curis (CRIS), and Vaxart (VXRT). These companies are all part of the "biological products, except diagnostic" industry.
BioAtla (NASDAQ:BCAB) and aTyr Pharma (NASDAQ:LIFE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership, community ranking and dividends.
BioAtla has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.
BioAtla's return on equity of -49.84% beat aTyr Pharma's return on equity.
77.2% of BioAtla shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 8.4% of BioAtla shares are held by company insiders. Comparatively, 3.7% of aTyr Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
aTyr Pharma received 398 more outperform votes than BioAtla when rated by MarketBeat users. However, 66.67% of users gave BioAtla an outperform vote while only 61.40% of users gave aTyr Pharma an outperform vote.
aTyr Pharma has higher revenue and earnings than BioAtla. aTyr Pharma is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.
In the previous week, BioAtla and BioAtla both had 2 articles in the media. BioAtla's average media sentiment score of 0.30 beat aTyr Pharma's score of 0.00 indicating that aTyr Pharma is being referred to more favorably in the news media.
BioAtla currently has a consensus price target of $11.00, indicating a potential upside of 341.77%. aTyr Pharma has a consensus price target of $23.67, indicating a potential upside of 1,388.47%. Given BioAtla's higher probable upside, analysts clearly believe aTyr Pharma is more favorable than BioAtla.
Summary
aTyr Pharma beats BioAtla on 9 of the 15 factors compared between the two stocks.
Get aTyr Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIFE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LIFE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
aTyr Pharma Competitors List
Related Companies and Tools
